Savaria (SIS) Q2 2026 earnings summary

Executive summary

• Achieved record quarterly revenue of CAD 246 million (USD 245.8M), up 8.4% year-over-year, with balanced growth in both patient care and accessibility segments across North America and Europe.

• Adjusted EBITDA reached CAD 51.8 million, margin at 21.1%, reflecting operational improvements and the Savaria One initiative.

• Growth was driven by organic initiatives, new product launches, and acquisitions, including Baxter Elevator in Texas and Vipal S.p.A. in Italy.

• Strong performance and expansion of product offerings and manufacturing capabilities in both North America and Europe.

• Acquisition of Vipal S.p.A. on July 1, 2026, expected to enhance European market presence.

Financial highlights

• Q2 2026 revenue grew 8.4% year-over-year to CAD 245.8 million, with 6.6% organic growth and 0.8% from acquisitions.

• Adjusted EBITDA margin improved to 21.1%, up 50 basis points from last year.

• Net earnings increased 54.4% to CAD 25.2 million (CAD 0.34 per diluted share) compared to Q2 2025.

• Gross profit was CAD 97.3 million, up 9.9%, with gross margin at 39.6%.

• Net debt-to-EBITDA ratio improved to 0.87, with available liquidity of CAD 333 million.

Outlook and guidance

• Targeting approximately 12% annual revenue growth through 2030, aiming for CAD 1.6 billion in sales and EBITDA over CAD 220 million by 2030.

• Plans to maintain adjusted EBITDA margins above 20% and increase adjusted EBITDA per share to ~$4.25 by 2030.

• Growth to be driven by organic initiatives, new product lines, acquisitions, and continuous improvement.

• Plans for further acquisitions totaling approximately CAD 200 million over the next five years.